Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
4(29%)
Results Posted
17%(1 trials)
Terminated
2(14%)

Phase Distribution

Ph phase_1
1
7%
Ph not_applicable
3
21%
Ph phase_2
6
43%
Ph phase_3
3
21%

Phase Distribution

1

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
6(46.2%)
Phase 3Large-scale testing
3(23.1%)
N/ANon-phased studies
3(23.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

4

trials recruiting

Total Trials

14

all time

Status Distribution
Active(5)
Completed(6)
Terminated(3)

Detailed Status

Completed6
Active, not recruiting2
Terminated2
Recruiting2
Withdrawn1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
4
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (7.7%)
Phase 26 (46.2%)
Phase 33 (23.1%)
N/A3 (23.1%)

Trials by Status

active_not_recruiting214%
terminated214%
withdrawn17%
completed643%
not_yet_recruiting17%
recruiting214%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT05639647Phase 2

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Recruiting
NCT06075706Phase 2

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

Active Not Recruiting
NCT05905055Phase 3

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

Completed
NCT04629833Phase 3

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting
NCT02577926Phase 2

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Active Not Recruiting
NCT05685615Phase 2

PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB

Completed
NCT06593834Not Applicable

A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation

Not Yet Recruiting
NCT02055183

BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin

Completed
NCT03580044Phase 3

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

Terminated
NCT04366908Phase 2

Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome

Completed
NCT02572024Not Applicable

The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study)

Completed
NCT04954014Phase 2

Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients

Terminated
NCT02666287Phase 1

GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)

Completed
NCT01523925Not Applicable

Combined Behavioral Approaches With Functional Electrical Therapy in Stroke Rehabilitation

Withdrawn

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14